Krystal Biotech, Inc. KRYS Business Segments — R&D
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Krystal Biotech, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Krystal Biotech, Inc.'s business segments — r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Krystal Biotech, Inc.'s business segments — R&D?
- Krystal Biotech, Inc. (KRYS) reported business segments — R&D of $15.33M in Q1 2026.
- How has Krystal Biotech, Inc.'s business segments — R&D changed year-over-year?
- Krystal Biotech, Inc.'s business segments — R&D increased by 7.5% year-over-year, from $14.26M to $15.33M.
- What is the long-term trend for Krystal Biotech, Inc.'s business segments — R&D?
- Over 3 years (2022 to 2025), Krystal Biotech, Inc.'s business segments — R&D has grown at a 11.0% compound annual growth rate (CAGR), from $42.46M to $58.05M.
- What does business segments — R&D mean?
- The total spending on scientific research and clinical trials to develop new products.
- How do you interpret business segments — R&D?
- An increase reflects a commitment to pipeline expansion, while a decrease may signal a shift toward commercialization or cost-cutting measures.
- How does business segments — R&D compare across companies?
- High R&D spending is standard for clinical-stage biotech companies, often representing the largest portion of operating expenses.